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REAL-WORLD TRENDS IN THE DIAGNOSIS AND ASSESSMENT OF 
RHEUMATOID ARTHRITIS (RA) AMONG RHEUMATOLOGISTS IN  
THE UNITED STATES
DiBonaventura M1, Roy S2, Ertl J1, Cifaldi M2
1KantarHealth, New York, NY, USA, 2Abbott Laboratories, Abbott Park, IL, USA
OBJECTIVES: Diagnosis and management of rheumatoid arthritis (RA) have changed 
dramatically during the last several years, with the emergence of new guidelines, treat-
ment options, and diagnostic tests. These involve varying degrees of complexity, and 
place demands on time and resources in routine clinical practice. The aim of this study 
was to assess current trends in RA diagnosis and assessment practices among US 
rheumatologists. METHODS: A sample of rheumatologists (N = 86) was surveyed 
online through an actively-managed Internet panel. Physicians were asked which 
diagnostic and disease severity measures they were aware of, and how often they used 
those measures—for both diagnosis and disease severity assessment. RESULTS: Physi-
cians were mostly male (n = 62, 72.1%) and practiced in suburban areas (n = 44, 
51.2%). The mean number of years in practice (post-residency) was 16.3, and the 
mean number of RA patients seen per month was 136.5. Physicians treated more RA 
patients with disease-modifying antirheumatic drugs (DMARDs) and biologics than 
with non-steroidal anti-inﬂammatory drugs (NSAIDS), COX-2 inhibitors, and corti-
costeroids. The most common diagnostic measure was anti-cyclic citrullinated peptide 
(anti-CCP) assays (97.7%). The most common disease assessments were swollen joint 
count (88.4%), tender joint count (87.2%), erythrocyte sedimentation rate (81.4%), 
C-reactive protein (77.9%), patient’s assessment of physical function (75.6%), and 
patient’s assessment of pain (74.4%). 54 physicians (62.7%) reported employing 
HRQOL questionnaires to assess patients’ well-being, the Health Assessment Ques-
tionnaire (HAQ) being the most common (43.4%). CONCLUSIONS: Though rela-
tively new, anti-CCP assays were employed by almost all physicians for RA diagnoses. 
While other serum markers were often used for diagnosis, they were less likely to be 
used for disease severity assessment versus physicians’ and patients’ assessments of 
symptoms and physical function. Although a majority of physicians used HRQOL 
measures, the opportunity exists for further adoption and standardization of such 
measures to facilitate better management of RA.
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TWO YEAR MAINTENANCE INFLIXIMAB DOSING AND 
ADMINISTRATION PATTERNS IN PATIENTS WITH RHEUMATOID 
ARTHRITIS
Bailey R1, Bolge S1, Ernst FR2, Johnson B2, McKenzie RS1
1Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, 2Premier, Inc, Charlotte, NC, 
USA
OBJECTIVES: Food and Drug Administration (FDA)-approved prescribing informa-
tion recommends inﬂiximab (IFX) administration at 0, 2, 6 and every 8 weeks with 
potential dose increase based on patient response for patients with RA. Minimal real 
world dosing data are available in this population. This study evaluated IFX dosing 
patterns in patients with rheumatoid arthritis (RA) treated in the outpatient hospital 
setting. METHODS: A retrospective longitudinal analysis using the Premier Perspec-
tiveTM Database, a United States-based hospital database, was conducted. Inclusion 
criteria were an outpatient hospital discharge RA diagnosis (ICD-9 code 714.xx) 
between July 1, 2000 and December 31, 2008, IFX-naïve, and ≥3 IFX doses within 
≤56 days of the index infusion. Exclusion criteria included patients with other selected 
inﬂammatory diseases. Treatment duration was deﬁned as the time between the index 
and last IFX dose. The 4th through 15th IFX doses were analyzed representing the ﬁrst 
2 years of IFX maintenance treatment. RESULTS: A total of 2185 patients with RA 
receiving IFX were identiﬁed. Mean (SD) age was 60.3 (14.0) years; 79.0% were 
female. Mean (SD) treatment duration was 465 (459) days. Patients received a mean 
(SD) of 9.9 (8.8) IFX administrations. Mean (SD) index IFX dose was 338.2 (156.8) 
mg. Mean (SD) maintenance IFX dose was 387.7 (169.5) mg. During the initial two 
years of IFX administration, mean doses remained between 351 and 402 mg. During 
the initial two years of maintenance IFX administration, the highest observed mean 
dose represented a 15% increase compared to the ﬁrst dose in the maintenance period 
and a 19% increase compared to index dose. Median time between administrations 
was 55 days for all maintenance infusions. CONCLUSIONS: The observed adminis-
tration schedule was consistent with FDA-approved prescribing information. These 
data suggest the IFX dose in patients with RA remained relatively stable and provide 
stakeholders with an understanding of real world utilization.
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DOSES AND INFUSION INTERVALS FOR INFLIXIMAB IN ANTI-TNF 
NAïVE AND ANTI-TNF EXPERIENCED MANAGED CARE PATIENTS 
WITH RHEUMATOID ARTHRITIS
Carter C1, Tang B1, Changolkar A2, McKenzie RS1, Piech CT1
1Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, 2SOAL PharmaTech Solutions, 
LLC, Phildelphia, PA, USA
OBJECTIVES: To describe inﬂiximab (IFX) doses and infusion intervals in patients 
with RA who are anti-TNF naïve or anti-TNF experienced. METHODS: Medical and 
pharmacy claims for patients ≥18 years with ≥2 RA diagnosis codes received January 
2000-December 2006 were included from a database of commercial health plans. 
Patients were excluded for selected inﬂammatory conditions. Anti-TNF naïve patients 
had no biologic use for 6 months prior to IFX. Anti-TNF experienced patients had 
adalimumab/etanercept prior to IFX. Infused doses were calculated by dividing the 
plan’s allowed amount for each IFX claim by the acquisition cost for a 100 mg vial. 
Results were reported for induction (weeks 0–8), maintenance (weeks 9–52), and 
one-year (weeks 0–52) periods. Infusion intervals included mean time (days) between 
infusions during the ﬁrst year of treatment. RESULTS: A total of 425 naïve (mean 
age = 53 years; 74% female) and 467 experienced (mean age = 49 years; 78% female) 
patients were evaluated. The mean IFX dose per infusion for naïve patients was lower 
during the induction vs. maintenance period (397 mg vs. 455 mg). The mean IFX dose 
per infusion for one year was 437 mg. Nearly all naïve patients (98.5%) received no 
more than 8 infusions in the ﬁrst year. The mean times between IFX infusions for 
naïve patients were 19, 29, 56, 57, 55, 52, and 53 days. The mean IFX dose per 
infusion for experienced patients was lower during the induction vs. maintenance 
period (428 mg vs. 527 mg). The mean times between IFX infusions for experienced 
patients were 18, 28, 52, 50, 49, 48, and 41 days. CONCLUSIONS: This observa-
tional study reveals IFX utilization differences between anti-TNF naïve and experi-
enced patients. Both naïve and experienced patients had infusion intervals within the 
recommended labeling.
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DISPARITIES IN DISEASE MODIFYING ANTI-RHEUMATOID TREATMENT 
IN RHEUMATOID ARTHRITIS
Kawatkar AA1, Nichol MB2
1Kaiser Permanente Southern California, Pasadena, CA, USA, 2University of Southern 
California, Los Angeles, CA, USA
OBJECTIVES: The study objective was to quantify disparities in treatment choice of 
disease modifying anti-rheumatoid drugs (DMARD) used in Rheumatoid Arthritis. 
METHODS: Retrospective cohorts were constructed from California Medicaid paid 
insurance claims between January 1, 1998 to December 31, 2005. Non-overlapping 
monthly episodes were created from pharmacy claims for biologic (adalimumab and 
etanercept) and standard (methotrexate, leﬂuonomide, hydroxychloroquine and sul-
fasalazine) DMARDs. Final sample included 59,788 observations on 7,025 patients. 
Relative risk ratios (RRR) of factors associated with DMARD treatment choice were 
assessed by a multinomial logit model with baseline as methotrexate treatment. 
Covariates included age, gender, race, location of beneﬁciary’s county in either North-
ern or Southern California, population density in beneﬁciaries county, exclusive fee-
for-service reimbursement used in beneﬁciary’s county, Medicare and Medicaid dual 
eligibility, Elixhauser comorbidities index excluding Rheumatoid arthritis, and expen-
ditures associated with pharmacy, out-patient, inpatient, inpatient-MD, LTC, and ER 
visits in the three months prior to treatment. Hypothesis testing was based on cluster 
robust standard errors to control intra-individual correlations. RESULTS: The mean 
age was 58.6 (± 14.5) years with a majority of females (84.0%) and Caucasians 
(37.6%). All the covariates were unbalanced between the six treatment groups. Sta-
tistically signiﬁcant association was observed between choice of DMARD treatment 
and all the covariates. Females were less likely to use sulfasalazine (RRR = 0.64, p < 
0.001), but more likely to use hydroxychloroquine (RRR = 1.45, p = 0.001). The 
elderly patients were less likely to receive biologics as compared to methotrexate. 
Patients residing in high population density locations were more likely to receive 
biologic DMARDs. Hispanics were the only race more likely to receive adalimumab 
(RRR = 1.92, p = 0.001), as compared to Caucasians. CONCLUSIONS: Results 
signify marked evidence of socio-demographic disparity in DMARD treatment for RA, 
and also highlights the variation in DMARD utilization based on geography, and type 
of reimbursement.
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CONCORDANCE OF NONSTEROIDAL ANTI-INFLAMMATORY DRUG 
PRESCRIPTIONS WITH RECENT CLINICAL PRACTICE GUIDELINES IN 
QUEBEC, CANADA
Rahme E1, Roussy JP2, Lafrance JP3, Nedjar H1, Morin S4
1McGill University Health Centre, Montréal, QC, Canada, 2Pﬁzer Canada, Kirkland, QC, 
Canada, 3Hôpital Maisonneuve-Rosemont, Montréal, QC, Canada, 4Hôpital Général de 
Montréal, Montréal, QC, Canada
OBJECTIVES: Canadian guidelines for adequate nonsteroidal anti-inﬂammatory drug 
(NSAID) utilisation in patients with gastrointestinal (GI), cardiovascular (CV), con-
gestive heart failure (CHF) and renal risk factors have been recently published. The 
objective is to describe concordance of NSAID utilisation with current clinical practice 
guidelines during two time-periods: April 1, 2005 to March 31, 2007 (post- rofecoxib 
withdrawal period) and April 1, 2002 to March 31, 2004 (pre-rofecoxib withdrawal 
period) in Quebec, Canada. METHODS: Data were obtained from the physician and 
medication claims databases of the Quebec Health Insurance Agency. All prescriptions 
for celecoxib or traditional NSAIDs (tNSAIDs) dispensed to patients 50 years of age 
or older were evaluated for concordance with the guidelines. Prescriptions were strati-
ﬁed by patient GI, CV, CHF and renal risk factors and four risk categories (low, 
moderate, high, and very high) were considered in each condition (GI, CV, CHF and 
renal). RESULTS: Of celecoxib prescriptions, 87.2% were adequate in the post-period 
and 86.5% in the pre-period; while adequate prescriptions for tNSAIDs were 72.6% 
in the post-period and 70.1% in the pre-period. Inadequate prescriptions for celecoxib 
in the post-period were those prescribed to the low GI risk group (10.1%) and to 
either the very high renal risk group (1.3%) or very high CHF risk group (1.7%). In 
the post-period, 4,457 (0.5%) prescriptions of celecoxib in the low or moderate GI 
risk groups received a gastroprotective agent (GPA) co-prescription that was not 
apparently adequate. Among celecoxib prescriptions requiring a GPA co-prescription 
as per recent guidelines, only 30.0% had one that was adequate. Similarly, only 30.0% 
of the tNSAID prescriptions dispensed to those with GI risks received a GPA co-
prescription. CONCLUSIONS: About 87% of celecoxib and 70% of tNSAID pre-
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scriptions were adequate in both study periods according to recent guidelines. GPA 
co-prescription with NSAIDs remains greatly suboptimal.
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INDIRECT TREATMENT COMPARISONS OF BIOLOGIC THERAPIES FOR 
RHEUMATOID ARTHRITIS
Alfonso R, Devine B, Sullivan SD
University of Washington, Seattle, WA, USA
OBJECTIVES: To compare the efﬁcacy results of biological therapies for rheumatoid 
arthritis (RA) using indirect treatment comparisons and meta-regression techniques. 
METHODS: We performed a literature search to identify the randomized clinical trials 
(RCTs) of biological therapies for RA. Using these studies we created a network and 
developed two random effects, logistic regression models (6- and 12-months), using 
the ACR-50 as the primary outcome. We chose mean disease duration and mean 
baseline HAQ-DI score as meta-regression covariates, to account for heterogeneity 
between trials, as these have prognostic value in determining the effect of RA treat-
ment. RESULTS: We included 18 RCTs in the 6-month analysis and 10 RCTs in the 
12-month analysis. Eight biologic agents are included in the 6-month analysis and six 
in the 12-month. The results of the 6-month analysis suggest that the eight biologic 
agents are signiﬁcantly more effective than the comparator (p < 0.05): Certulizumab 
(log odds ratio, median = 2.6), rituximab (1.7), adalimumab (1.6), inﬂiximab (1.6), 
etanercept (1.4), golimumab (1.3), abatacept (1.2), and anakinra (1.0). The results 
also indicate that methotrexate (MTX) is signiﬁcantly more effective than placebo 
(0.7). The parameter values for the 12-month analysis are similar, with the effective-
ness of the biologics following the same order, but without golimumab and anakinra. 
CONCLUSIONS: Our results suggest that biologic treatments are more effective than 
MTX or placebo, but they may differ from one another. There are differences in the 
outcomes depending on whether we evaluate the ACR-50 at 6-months or 12-months. 
Biologic agents seem to be more effective with longer disease duration.
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A NEW METHODOLOGY TO ASSESS CLINICAL CHANGE USING 
CHARTS IN RHEUMATOID ARTHRITIS (RA) PATIENTS ON TNF 
BLOCKERS
Bonafede RP1, Segal S2, Lautzenheiser R3, Loveless J4, Watson C5, Harrison DJ5
1Providence Arthritis Center, Portland, OR, USA, 2Sansum Clinic, Santa Barbara, CA, USA, 
3Rheumatology Associates, Indianapolis, IN, USA, 4Intermountain Orthopaedics, Boise, ID, 
USA, 5Amgen, Newbury Park, CA, USA
BACKGROUND: Charting across practices for RA patients varies greatly and rarely 
uses formal measures to assess treatment effectiveness outside clinical trials. OBJEC-
TIVES: To develop a tool to assess treatment effectiveness in real-world practice using 
information commonly found in charts. METHODS: From an ongoing chart audit, a 
sample of ten de-identiﬁed charts of RA patients initiating TNF blocker treatment was 
reviewed by four clinical rheumatologists to determine useful variables commonly 
found in charts. National guidelines were reviewed to determine which variables are 
used to assess treatment effectiveness in clinical trials. A scale was created and deﬁned 
for each variable. Criteria to assign an overall outcome change score from baseline 
through follow-up were created. Three additional rheumatologists were added to test 
the scale using 51 additional charts. Each chart was reviewed by two pairs of rheu-
matologists. Sufﬁcient inter-rater reliability could not be achieved due to lack of 
consistent data, so differences in ratings were reconciled by discussion between raters 
and ﬁnal scores were assigned by consensus. If consensus could not be reached, a third 
pair of rheumatologists reviewed the chart and the ﬁnal score was assigned by con-
sensus. RESULTS: Key available variables identiﬁed were: patient joint pain, synovitis, 
patient global assessment, lab markers (CRP and ESR), patient-reported outcomes 
surveys, and other (fatigue, physician global assessment, morning stiffness, and radio-
graphic information). All variables were scored much worse, worse, no change, better, 
and much better from the baseline to the follow-up visit. An overall outcome change 
score was assigned using the same scale. Missing data were considered no change. 
Clinical judgment was an essential component to the score. Agreement was good 
between pairs of raters; 53% of initial scores matched and 39% were within one 
category. CONCLUSIONS: A rating scale can be applied by experienced clinicians 
and used for comparative effectiveness research.
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OPERATIVE RISK OF STAGED BILATERAL KNEE REPLACEMENT IS 
UNDER-ESTIMATED IN RETROSPECTIVE STUDIES
Kim S, Meehan JP, White RH
University of California, Davis, Sacramento, CA, USA
OBJECTIVES: Surgical options for patients with symptomatic bilateral knee osteoar-
thritis are 1) simultaneous bilateral total knee arthroplasty (BTKA) under one anes-
thesia and 2) staged total knee arthroplasty (STKA) with two distinct operations 
separated by a few days up to one year. A number of studies have compared post-
operative complications after BTKA versus STKA by simply collecting and then 
contrasting outcomes collected retrospectively. However, this methodology is biased 
because it fails to account for the patients who had STKA planned but who never 
completed the second stage because they died or developed a serious post-operative 
complication after the ﬁrst operation, leading to cancellation of the second STKA. The 
purpose of this study was to demonstrate the misclassiﬁcation bias associated with 
simply comparing operative outcomes after BTKA versus STKA. METHODS: To 
demonstrate the bias, a mathematical derivation and graphical presentation were 
developed. RESULTS: First, we mathematically demonstrated that the observed pro-
portion of complication (Pobserved) in patients who completed both STKA operations 
underestimates the true proportion of complication (Ptrue). Second, we graphically 
demonstrated that STKA always appears to be safer than BTKA even if when the 
proportion of post-operative complications observed is held constant. When data were 
simulated using a true odds ratio of 1, the observed odds ratio ranged from 0.899 to 
0.557 for various combination of other probabilities.CONCLUSIONS: Most pub-
lished studies have reported that post-operative complications are lower for STKA 
compared with BTKA. However, our analysis indicates that any conclusions based 
simply on retrospective analysis of subjects who successfully completed STKA is biased 
because it includes only cases that recovered after the ﬁrst operation rather than all 
of the patients that had STKA planned. Absent a prospective study, the only fair and 
unbiased comparison of post-operative complications between STKA and BTKA 
requires adjustments to account for this bias.
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USE OF A DISEASE-SPECIFIC INSTRUMENT IN ECONOMIC 
EVALUATIONS: MAPPING WOMAC ONTO THE EQ-5D UTILITY INDEX
Xie F1, Pullenayegum E2, Li SC3
1PATH Research Institute, McMaster University, Hamilton, ON, Canada, 2McMaster 
University, Hamilton, ON, Canada, 3University of Newcastle, School of Biomedical Sciences, 
Callaghan, NSW, Australia
OBJECTIVES: To map the Western Ontario and McMaster Universities Osteoarthritis 
Index (WOMAC) onto the EQ-5D utility index in patients with knee osteoarthritis 
(OA). METHODS: A consecutive sample of patients (n = 258) with diagnosed knee 
OA completed both the WOMAC and the EQ-5D. Regression models with ordinary 
least squares (OLS) or the censored least absolute deviations (CLAD) as the estimator 
were used to establish the mapping function. The WOMAC was represented as 
explanatory variables in four ways: (a) total score; (b) domain scores (i.e., pain, stiff-
ness, and physical function), (c) domain scores plus pairwise interaction terms to 
account for possible nonlinearities; and (d) individual item scores. Goodness-of-ﬁt 
criteria included mean absolute error (MAE, the primary criterion) and root mean 
squared error (RMSE) obtained using an iterative random sampling procedure. Predic-
tion precision was evaluated at individual patient level and at the group level. 
RESULTS: The model using OLS estimator and WOMAC domain scores as explana-
tory variables had the best ﬁt and was chosen as the preferred mapping model. The 
prediction error at individual level exceeded the maximal tolerance value (i.e. the 
minimally important difference of EQ-5D) in about 16% of patients. At group level, 
the width of 95% CI of prediction errors varied from 0.0176 at a sample size of 400 
to 0.0359 at a sample size of 100. CONCLUSIONS: EQ-5D scores can be predicted 
using WOMAC domain scores with an acceptable precision at both the individual and 
group levels in patients with mild to moderate knee OA.
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METHODS FOR INTERPRETING TUMOR NECROSIS FACTOR (TNF) 
BLOCKER DOSING AND TREATMENT PATTERNS FROM PHARMACY 
AND PROFESSIONAL CLAIMS
Makin C1, Schabert V2, Harrison DJ3, Goodman S4
1IMS Health, Plymouth Meeting, PA, USA, 2IMS Health, Santa Barbara, CA, USA, 3Amgen, 
Newbury Park, CA, USA, 4IMS Health, Watertown, MA, USA
OBJECTIVES: Despite using fully adjudicated claims, analyzing biologics treatment 
patterns requires reliable data cleaning and imputation methods for both pharmacy 
and professional claims. Self-injected agents with longer dosing intervals present 
unique challenges for data analysis. We developed methods to improve interpretability 
while minimizing data loss using TNF blocker claims. METHODS: A large health 
plan claims database was used to obtain 3,725 Psoriasis and/or Psoriatic Arthritis 
subjects initiating adalimumab (ADL) or etanercept (ETN) between January 1, 2003 
and March 31, 2009; and were enrolled for 360 days pre- and ≥180 days post-index 
(ﬁrst TNF claim). Patients were excluded if they had other inﬂammatory disorders 
pre- or post-index or received any biologic pre-index. We reviewed patients’ drug 
dispensing histories, established acceptable ranges for key claim values, and developed 
imputation rules that leveraged allowed reimbursements and dispensed quantities 
when other values were discrepant or missing. For professional claims, we divided 
total doses across weeks between ﬁlls to obtain average weekly dose. RESULTS: A 
total of 89.2% of 46,206 ETN and 94.6% of the 3,470 ADL claims were from 
pharmacies. 9.7% subjects with ≤0 reimbursed amounts on index were excluded, as 
were 0.9% with extreme quantity values (>48/ >16 for ETN pharmacy/professional 
claims, >12 for ADL) and 1.0% patients with extreme weekly dose values in any claim 
(>250 mg for ETN, >200 mg for ADL). 8.8% subjects had >1 same-day claims, which 
were sorted in descending order of charge, allowed, and paid, with the top claim 
retained. After these steps, 3065 (82.3%) subjects remained in the cohort. CONCLU-
SIONS: Analyzing TNF blocker treatment patterns from claims requires adjustments 
for weekly dosing schedules and for professional claims that reﬂect dispensing of 
supplies for home injection. However, the limited dosing schedules for ADL and ETN 
allow for data cleaning strategies that address these challenges while retaining the vast 
majority of data.
